Eli Lilly and Company (NYSE:LLY) Shares Sold by Parker Investment Management LLC

Parker Investment Management LLC decreased its position in Eli Lilly and Company (NYSE:LLY) by 55.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,365 shares of the company’s stock after selling 6,777 shares during the period. Eli Lilly and Company accounts for approximately 0.8% of Parker Investment Management LLC’s investment portfolio, making the stock its 12th largest position. Parker Investment Management LLC’s holdings in Eli Lilly and Company were worth $4,754,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Lantz Financial LLC grew its position in shares of Eli Lilly and Company by 1.3% during the second quarter. Lantz Financial LLC now owns 1,236 shares of the company’s stock worth $1,119,000 after buying an additional 16 shares in the last quarter. Abacus Wealth Partners LLC grew its holdings in Eli Lilly and Company by 6.0% during the 2nd quarter. Abacus Wealth Partners LLC now owns 550 shares of the company’s stock worth $498,000 after acquiring an additional 31 shares in the last quarter. First Financial Corp IN increased its position in shares of Eli Lilly and Company by 22.7% in the 2nd quarter. First Financial Corp IN now owns 5,410 shares of the company’s stock valued at $4,898,000 after purchasing an additional 1,002 shares during the last quarter. Lwmg LLC raised its holdings in shares of Eli Lilly and Company by 3.4% in the 2nd quarter. Lwmg LLC now owns 1,048 shares of the company’s stock valued at $948,000 after purchasing an additional 34 shares in the last quarter. Finally, Cherrydale Wealth Management LLC raised its holdings in shares of Eli Lilly and Company by 10.0% in the 2nd quarter. Cherrydale Wealth Management LLC now owns 737 shares of the company’s stock valued at $667,000 after purchasing an additional 67 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently commented on LLY shares. Evercore ISI raised Eli Lilly and Company to a “hold” rating in a report on Thursday, September 5th. Cantor Fitzgerald reissued an “overweight” rating and set a $885.00 target price on shares of Eli Lilly and Company in a research report on Monday, September 16th. JPMorgan Chase & Co. upped their price target on Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the company an “overweight” rating in a report on Friday, September 13th. Citigroup raised their price objective on Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the stock a “buy” rating in a report on Friday, October 25th. Finally, Bank of America reduced their price objective on Eli Lilly and Company from $1,150.00 to $1,100.00 and set a “buy” rating for the company in a research note on Thursday, October 31st. Four investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,007.94.

Eli Lilly and Company Stock Up 1.7 %

Eli Lilly and Company stock opened at $813.33 on Wednesday. The stock’s 50 day moving average price is $847.28 and its 200 day moving average price is $871.36. Eli Lilly and Company has a 1-year low of $561.65 and a 1-year high of $972.53. The company has a market cap of $772.11 billion, a PE ratio of 87.93, a price-to-earnings-growth ratio of 3.03 and a beta of 0.41. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 0.97.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 EPS for the quarter, missing the consensus estimate of $1.52 by ($0.34). Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The company had revenue of $11.44 billion during the quarter, compared to analyst estimates of $12.09 billion. During the same quarter last year, the business earned $0.10 EPS. The firm’s revenue for the quarter was up 20.4% on a year-over-year basis. On average, sell-side analysts predict that Eli Lilly and Company will post 13.2 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Friday, November 15th will be given a $1.30 dividend. The ex-dividend date is Friday, November 15th. This represents a $5.20 annualized dividend and a dividend yield of 0.64%. Eli Lilly and Company’s dividend payout ratio is presently 56.22%.

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of the company’s stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $803.38, for a total value of $723,042.00. Following the transaction, the chief accounting officer now directly owns 5,480 shares in the company, valued at approximately $4,402,522.40. This represents a 14.11 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.13% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.